CUV clinuvel pharmaceuticals limited

Clinuvel compared to Imugene, page-27

  1. 7,705 Posts.
    lightbulb Created with Sketch. 2797

    This makes completely no sense when they are growing revenue/profits over 50% easily and have zero debt and zero chance of going broke and they have an absolute market monopoly for years to come in the EPP space!

    CUV has one orphan drug with a very limited market. They have no other products. The market look ahead and sees the Scenesse monopoly ending in a few years. The patents will begin to expire soon. It is possible sales will fall to almost zero if better or cheaper alternatives are available. That is how the pharmaceutical industry works.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$10.61
Change
-0.160(1.49%)
Mkt cap ! $533.8M
Open High Low Value Volume
$10.60 $10.72 $10.54 $275.7K 25.96K

Buyers (Bids)

No. Vol. Price($)
1 144 $10.61
 

Sellers (Offers)

Price($) Vol. No.
$10.62 119 6
View Market Depth
Last trade - 12.51pm 16/07/2025 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.